Price C$0.51: Sweet Earth Holdings (SE.CN CNQ) oversold bounce watch 25 Feb 2026
SE.CN stock trades at C$0.51 on the CNQ market during regular hours on 25 Feb 2026, putting Sweet Earth Holdings Corporation within a potential oversold bounce setup we are monitoring. Volume is light at 2,100.00 shares but the 50-day average sits at C$0.56 and the 200-day average at C$0.37, creating a short-term resistance and a longer-term support zone. We highlight valuation metrics, liquidity limits, and a clear trade plan for buyers who want a disciplined oversold bounce approach.
SE.CN stock current snapshot
Sweet Earth Holdings Corporation (SE.CN) is priced at C$0.51 on the CNQ exchange in Canada. Day range is C$0.51–C$0.51, previous close C$0.52, year high C$0.74, year low C$0.10, and market cap C$6,586,663.00. Key per-share metrics: EPS C$0.21, trailing PE 2.43, shares outstanding 12,915,025.00, volume 2,100.00 and average volume 2,994.00. The 50-day average price is C$0.56 and the 200-day average is C$0.37, both relevant to an oversold bounce entry.
Technical setup for SE.CN stock: oversold bounce criteria
Price below the 50-day average but above the 200-day average fits a classic oversold bounce candidate. Short-term momentum shows a 3-month drop of -19.05% while YTD is +27.50% and 1-year is +70.00%, indicating recent volatility. Low liquidity is a constraint: relative volume 0.70 and average daily volume 2,994.00 shares. Tactical levels: a conservative entry near C$0.51, initial resistance at the 50-day C$0.56, and a clear stop-loss below C$0.46 to limit downside. Watch for volume pickup above 4,000.00 shares to confirm a reliable bounce.
Fundamentals and valuation for SE.CN stock
Sweet Earth operates in Healthcare, focused on CBD and hemp products in the US and Spain. Trailing metrics show mixed signals: reported EPS C$0.21 gives a PE of 2.43, while some trailing accounting metrics show negative net income per share on a different window. Cash per share is C$0.22 and book value per share is near zero. Current ratios and debt metrics are weak and operating cash flow per share is negative at -0.09, which raises financing risk for growth. For valuation, low market cap and a low price create big percentage moves but also magnify fundamental risk.
Meyka AI grade and model context for SE.CN stock
Meyka AI rates SE.CN with a score out of 100: 62.58 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects small size, mixed cash flow metrics, and volatile price action. These grades are model outputs for informational purposes only; they are not guaranteed and we are not financial advisors. Meyka AI, an AI-powered market analysis platform, flags SE.CN as a speculative hold with selective trading setups.
Catalysts, risks and sector context for SE.CN stock
Catalysts that could trigger a bounce include clearer revenue growth, higher retail distribution for CBD lines, or clinical or marketing updates. There is limited company-specific news and broader consumer trends such as plant-based and wellness demand that can help product sales source. Regulatory shifts and advertising limits for CBD products remain key risks, and sector sentiment is muted with Healthcare YTD performance near -3.07%. Always weigh regulatory and liquidity risks before buying this small-cap name source.
Trade plan and price targets for SE.CN stock
We outline a strict oversold bounce trade plan: size positions small due to low liquidity and set a stop-loss at C$0.46. Short-term price target (mean-reversion) C$0.60 implies +17.65% upside from C$0.51. Medium-term target C$0.72 implies +41.18% upside and aligns with Meyka AI’s model outlook. Bull case target C$0.90 implies +76.47% upside but carries higher risk. Position sizing should cap exposure to single-digit percentages of a portfolio. Note trade costs and CAD execution on CNQ when placing orders.
Final Thoughts
SE.CN stock sits at C$0.51 on CNQ with a clear oversold bounce profile during market hours on 25 Feb 2026. The setup is driven by price below the 50-day average (C$0.56) and above the 200-day average (C$0.37), light volume, and mixed fundamentals that require careful risk control. For short-term traders we suggest a disciplined entry near C$0.51, stop-loss C$0.46, and a conservative target C$0.60. Meyka AI’s forecast model projects C$0.72 over a medium term, implying +41.18% versus the current price C$0.51; forecasts are model-based projections and not guarantees. Given small market cap C$6,586,663.00, weak cash flow per share, and regulatory sensitivity in the CBD sector, treat any position as speculative. Use strict stops, watch volume for confirmation above 4,000.00 shares, and update the trade if company news or sector rules change. We will continue monitoring SE.CN stock for a confirmed bounce and further fundamental signals.
FAQs
Is SE.CN stock a buy after the recent drop?
SE.CN stock shows an oversold bounce setup but remains speculative. Consider a small, disciplined trade with stop-loss at C$0.46 and confirmation from volume above 4,000.00 shares before increasing size.
What are realistic price targets for SE.CN stock?
Short-term target C$0.60 (+17.65%), medium-term Meyka AI forecast C$0.72 (+41.18%), and a bull case C$0.90 (+76.47%). These targets are model-based and not guarantees.
How risky is trading SE.CN stock on CNQ?
SE.CN stock carries high risk due to low liquidity, small market cap C$6,586,663.00, negative operating cash flow per share, and CBD regulatory uncertainty. Use small position sizes and strict stops.
Where can I find sector context that affects SE.CN stock?
Track consumer wellness trends and CBD regulation updates. Broader consumer shifts are covered by outlets like Fortune and real-time commentary on sites such as Seeking Alpha for market sentiment.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.